There are currently 27 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Autism participants are Florida, California, New York and Arizona.
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Recruiting
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers. Eligibility: Adults age 18 years and older in good general he... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/22/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dementia, Alzheimer's Disease, ALS, Parkinson's Disease
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/29/2024
Locations: MD First Research - Chandler, Chandler, Arizona +75 locations
Conditions: Alzheimer's Disease
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/29/2024
Locations: MD First Research - Chandler, Chandler, Arizona +48 locations
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
Recruiting
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/23/2024
Locations: Charter Research, Lady Lake, Florida +22 locations
Conditions: Alzheimer's Disease
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Recruiting
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Gender:
All
Ages:
Between 35 years and 85 years
Trial Updated:
02/20/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +16 locations
Conditions: Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
Recruiting
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
02/15/2024
Locations: Sage Investigational Site, Gilbert, Arizona +35 locations
Conditions: Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/12/2024
Locations: GSK Investigational Site, San Diego, California +103 locations
Conditions: Alzheimer's Disease
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
Recruiting
To investigate the impact of a long-term light treatment intervention on sleep physiology and memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The goal is also to measure the impact of the lighting intervention on caregivers' sleep, cognition, depression, and quality of life.
Gender:
All
Ages:
50 years and above
Trial Updated:
02/06/2024
Locations: Icahn School of Medicine at Mount Sinai, Albany, New York +1 locations
Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Retinal Imaging in Neurodegenerative Disease
Recruiting
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Mild Cognitive Impairment, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease, Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Normal Cognition
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/24/2024
Locations: Yale University, New Haven, Connecticut +1 locations
Conditions: Alzheimer's Disease
Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
Recruiting
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure.
Gender:
All
Ages:
65 years and above
Trial Updated:
12/05/2023
Locations: Icahn School of Medicine at Mount Sinai, Albany, New York +1 locations
Conditions: Alzheimer's Disease, Sleep Disturbance
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
Recruiting
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
12/01/2023
Locations: University of California - San Diego, La Jolla, California +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment